Pulmonary Hypertension - Global Market Research 2015-2019

PART 01: Executive summary
Highlights 
PART 02: Scope of  the report
Market overview 
Top-vendor offerings 
PART 03: Market research methodology
Research methodology 
Economic indicators 
PART 04: Introduction
Key market highlights 
PART 05: Market landscape
Market overview 
Market size and forecast 
Five forces analysis 
PART 06: Pipeline portfolio
Key Information of the few pipeline candidates 
PART 07: Market segmentation  by type of formulation
Oral 
Injection 
Inhalation 
PART 08: Market segmentation by mechanism of action
Endothelin receptor antagonist 
Prostacyclin analogues 
Phosphodiesterase inhibitors 
Soluble guanylate cyclase stimulators 
PART 09: Geographical segmentation
PART 10: Market drivers
Increase in incidence of pulmonary hypertension 
Patient assistance programs 
Newer disease modifying therapies 
Unmet medical needs 
PART 11: Impact of drivers
PART 12: Market challenges
Patent expiry 
Poor patient compliance 
Intense competition among vendors 
PART 13: Impact of drivers and challenges
PART 14: Market trends
Increased focus on combination therapies 
Increase in awareness of hypertension 
Strategic alliances 
PART 15: Vendor landscape
Competitive scenario 
Key news 
Mergers and acquisitions 
Market share analysis 2014 
Other prominent vendors 
PART 16: Key vendor analysis
Actelion Pharmaceuticals 
United Therapeutics 
GSK 
Bayer Healthcare 
PART 17: Appendix
List of abbreviation